Skip to main content

Table 1 Basic information on the most advertised drugs and drug groups

From: Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs

Advertised drug (n advertisements)

Brand name

EMA authorisationa

Marketing holderb

Drug groups

Beta2-agonist + steroid inhalations (28)

 Vilanterol + fluticasone furoate (11)

Relvar Ellipta

Nov 2013

GlaxoSmithKline

 Formoterol + budesonide (9)

DuoResp Spiromax

April 2014

Teva Pharma

 Formoterol + fluticasone propionate (8)

Flutiform

June 2012

Norpharma

Beta2-agonist + anticholinergic agents (26)

 Olodaterol + tiotropium (18)

Spiolto Respimat

N/Ac

Boehringer Ingelheim

 Vilanterol + umeclidinium (5)

Anoro Ellipta

May 2014

GlaxoSmithKline

 Formoterol + aclidinium bromide (3)

Duaklir Genuair

Nov 2014

Astra Zeneca

ADHD medications (16)

 Lisdexamfetamine (12)

Aduvanz

N/Ac

Shire Pharmaceuticals

 Atomoxetine (4)

Strattera

N/Ac

Eli Lilly

New oral anticoagulants (6)

 Rivaroxaban (4)

Xarelto

June 2013

Bayer

 Dabigatran (2)

Pradaxa

Aug 2011

Boehringer Ingelheim

Single drugs

 Paracetamol modified-release (15)

Panodil 665

N/Ac

GlaxoSmithKline

 Vortioxetine (8)

Brintellix

Dec 2013

Lundbeck

 Aripiprazole intramuscular depot (7)

Abilify Maintena

Nov 2013

Otsuka/Lundbeck

 Pneumococcal vaccine (6)

Prevenar 13

Jan 2010

Pfizer

 Canagliflozin (6)

Invokana

Nov 2013

Janssen-Cilag

  1. aWe used the EMA year of approval as a proxy for regulatory approval in Denmark. bThe marketing holder is the pharmaceutical company that also sponsors the advertisements. cWe where not able to find relevant information on the EMA website. These drugs were likely approved through decentralised procedures, which means that a European national drug regulator authorised the drug and not EMA